Immunovant (Nasdaq:IMVT) - Cotización, noticias y análisis

Resumen de acción IMVT

Immunovant, Inc. es una empresa biofarmacéutica en fase clínica que desarrolla anticuerpos monoclonales para el tratamiento de enfermedades autoinmunes. Saber más

Análisis fundamental de IMVT
Puntuación del snowflake
Valoración	2/6
Crecimiento futuro	2/6
Rendimiento pasado	0/6
Salud financiera	6/6
Dividendos	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 75.52%

Los analistas coinciden en que el precio de las acciones subirá un 70.3%

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Venta significativa por parte de personas con información privilegiada en los últimos 3 meses

Competidores de Immunovant, Inc.

CRISPR Therapeutics

NasdaqGM:CRSP

US$4.2b

Turning Point Therapeutics

NasdaqGS:TPTX

US$3.8b

RayzeBio

NasdaqGM:RYZB

US$3.7b

Rhythm Pharmaceuticals

NasdaqGM:RYTM

US$3.8b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Immunovant
Precios históricos de las acciones
Precio actual de la acción	US$28.73
Máximo en las últimas 52 semanas	US$45.58
Mínimo de 52 semanas	US$24.61
Beta	0.71
1Cambio en 1 mes	-4.07%
Variación en 3 meses	-7.26%
Cambio de 1 año	-24.87%
3Variación en 3 años	281.54%
Variación en 5 años	182.78%
Variación desde la OPV	188.74%

Noticias y actualizaciones recientes

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Oct 16

Immunovant: Switching Lead Candidates Increases Risk

Oct 14

Recent updates

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Jan 12

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Sep 28

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Jun 14

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Mar 08

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Nov 06

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Oct 17

Immunovant stock down on raising $75M though equity capital

Oct 04

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Aug 06

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Apr 06

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Jun 20

Immunovant EPS beats by $0.04

Jun 01

argenx rise even as Immunovant pauses the trial for anti-FcRn therapy

Feb 03

Immunovant slips 7% on voluntary hold of IMVT-1401 dosing

Feb 02

Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management

Jan 14

Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Dec 30

Immunovant (IMVT) Investor Presentation - Slideshow

Nov 16

Rentabilidad de los accionistas

	IMVT	US Biotechs	Mercado US
7D	9.8%	4.3%	1.6%
1Y	-24.9%	18.8%	32.3%

Rentabilidad vs. Industria: Los resultados de IMVT fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 18.8% el año pasado.

Rentabilidad vs. Mercado: IMVT obtuvo unos resultados inferiores a los del mercado US, que fueron del 32.3% el año pasado.

Volatilidad de los precios

Is IMVT's price volatile compared to industry and market?
IMVT volatility
IMVT Average Weekly Movement	6.3%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Precio estable de las acciones: IMVT no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de IMVT (6%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
n/a	207	Pete Salzmann	immunovant.com

Immunovant, Inc. es una empresa biofarmacéutica en fase clínica que desarrolla anticuerpos monoclonales para el tratamiento de enfermedades autoinmunes. La empresa desarrolla batoclimab, un nuevo anticuerpo monoclonal totalmente humano dirigido al receptor cristalizable de fragmentos neonatales para el tratamiento de la miastenia gravis, la enfermedad ocular tiroidea, la polineuropatía desmielinizante inflamatoria crónica, las enfermedades de Graves y la anemia hemolítica autoinmune caliente. Immunovant, Inc. tiene su sede en Nueva York, Nueva York.

Resumen de fundamentos de Immunovant, Inc.

¿Cómo se comparan los beneficios e ingresos de Immunovant con su capitalización de mercado?
Estadísticas fundamentales de IMVT
Capitalización bursátil	US$3.99b
Beneficios(TTM)	-US$323.01m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-13.1x

Ratio precio-beneficio (PE)

¿Está IMVT sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de IMVT
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$323.01m
Beneficios	-US$323.01m

Últimos beneficios comunicados

Sep 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-2.20
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado IMVT a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción IMVT

Recompensas

Análisis de riesgos

Competidores de Immunovant, Inc.

NasdaqGM:CRSP

US$4.2b

NasdaqGS:TPTX

US$3.8b

NasdaqGM:RYZB

US$3.7b

NasdaqGM:RYTM

US$3.8b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

CEO & Director recently sold US$425k worth of stock

Immunovant, Inc. Appoints Melanie Gloria as Chief Operating Officer, Effective November 18, 2024

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Immunovant: Switching Lead Candidates Increases Risk

Immunovant, Inc. Provides Update on Graves' Disease Development Program

CEO & Director recently sold US$480k worth of stock

Recent updates

CEO & Director recently sold US$425k worth of stock

Immunovant, Inc. Appoints Melanie Gloria as Chief Operating Officer, Effective November 18, 2024

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Immunovant: Switching Lead Candidates Increases Risk

Immunovant, Inc. Provides Update on Graves' Disease Development Program

CEO & Director recently sold US$480k worth of stock

Consensus EPS estimates fall by 17%

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant, Inc., Annual General Meeting, Aug 12, 2024

Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive

CEO & Director recently sold US$479k worth of stock

CEO & Director recently sold US$990k worth of stock

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

CEO & Director recently sold US$486k worth of stock

New major risk - Revenue and earnings growth

Immunovant: An Intriguing And Developing Story

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates

Independent Director recently sold US$491k worth of stock

Independent Director notifies of intention to sell stock

Immunovant, Inc. Announces Initial Data from 600 Mg MAD Cohort of A Phase 1 Clinical Trial of IMVT-1402 in Healthy Adults

CEO & Director recently sold US$532k worth of stock

Immunovant, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Immunovant, Inc. announced that it expects to receive $169.999992 million in funding from Roivant Sciences Ltd.

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant, Inc. Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Price target increased by 17% to US$34.42

CEO & Director recently sold US$1.3m worth of stock

Chief Financial Officer recently sold US$292k worth of stock

CEO & Director recently sold US$2.2m worth of stock

CEO & Director recently sold US$2.2m worth of stock

New minor risk - Insider selling

Immunovant, Inc., Annual General Meeting, Aug 21, 2023

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell Small Cap Comp Value Index

Price target increased by 14% to US$28.23

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Chief Financial Officer recently sold US$52k worth of stock

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Price target increased by 11% to US$20.25

Insider recently sold US$188k worth of stock

Chief Development & Technology Officer recently sold US$1.0m worth of stock

Price target increased to US$13.00

Less than half of directors are independent

Price target increased to US$11.00

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Chief Financial Officer recently sold US$118k worth of stock

Immunovant stock down on raising $75M though equity capital

Executive Chairperson of the Board recently bought US$116k worth of stock

Immunovant, Inc. Announces IMVT-1402

Immunovant Announces Two New Development Programs for Batoclimab

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant, Inc., Annual General Meeting, Aug 17, 2022

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell 2000 Growth Index

Immunovant, Inc. Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease

Immunovant, Inc. to Report Q4, 2022 Results on Jun 08, 2022